Ongoing clinical trials are investigating the impact of CTGF-targeting drugs like pamrevlumab on patients with pancreatic cancer.532 Integrins play a crucial role as mechanical signaling molecules in the stroma and have emerged as promising targets for slowing tumor progression. The gene discussed is CCN2; the disease is familial pancreatic carcinoma.